louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01826955: Effect of Pneumoperitoneum on Cognitive Function and Regional Cerebral Oxygen Saturation
Official title: Effect of Pneumoperitoneum on Cognitive Function and Regional Cerebral Oxygen
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pneumoperitoneum
Keywords: pneumoperitoneum, cognitive function
Lead sponsor: Gachon University Gil Medical Center
Sponsor class: OTHER
First posted: 2013-04-09
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patient who undergoing laparosopic or open gastrectomy patients who have respiratory and cardiovascular disorders were excluded

Brief summary: The investigators hypothesized that the pneumoperitoneum with reverse Trendelenburg position could alter the rSO2 and early postoperative cognitive function.

Detailed description: Laparoscopic gastrectomy requires a reverse-Trendelenburg position and prolonged pneumoperitoneum and it could cause significant changes in cerebral homeostasis and lead to cognitive dysfunction. We compared changes in haemodynamic variables, regional cerebral oxygen saturation, and early postoperative cognitive function in patients undergoing laparoscopic gastrectomy in the reverse Trendelenburg position with those patients that underwent conventional open gastrectomy.

Eligibility criteria: Inclusion Criteria:

* ASA class I or II, aged 20 to 70 yrs

Exclusion Criteria:

* Patients with morbid obesity (body mass index \> 30 kg/m2) or a history of cerebrovascular or respiratory disease were excluded.

Primary outcomes:
measure: MMSE
timeFrame: 5days after end of surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Incheon
country: Korea, Republic of
facility: Gachon University Gil Medical Center
Study officials:
affiliation: Gachon University Gil Medical Center
name: Hyun Jeong Kwak, M.D.
role: STUDY_DIRECTOR
References:
citation: Choi SH, Lee SJ, Jung YS, Shin YS, Jun DB, Hwang KH, Liu J, Kim KJ. Nitroglycerin- and nicardipine-induced hypotension does not affect cerebral oxygen saturation and postoperative cognitive function in patients undergoing orthognathic surgery. J Oral Maxillofac Surg. 2008 Oct;66(10):2104-9. doi: 10.1016/j.joms.2008.06.041.
Clinical trial NCT01201655: Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis
Official title: Multicentric Retrospective Case Control Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Liver Cirrhosis
Carcinoma, Hepatocellular
Splenomegaly
Laparotomy
Keywords: Posthepatitic cirrhosis;
Hepatocarcinogenesis;
Splenectomy;
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
Collaborators: name: Air Force Military Medical University, China
name: Xi'an Jiaotong University
First posted: 2010-09-14
Enrollment: 5000
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: post-hepatitic cirrhosis with portal hypertension and hypersplenism patients

Brief summary: The purpose of this study is to investigate the impact of splenectomy coupled with portal-azygous disconnection on hepatocarcinogenesis in patients with post-hepatitic cirrhosis after hepatitis B or C virus infection by retrospective case-control study,We hope to find a new idear and method to prevent or cure HCC.

Detailed description: A case-control study was carried out. The factors studied include age, gender, ascites, hepatic encephalopathy, ALT, AST, TBIL, ALP, GGT, Child-Pugh classification of liver function, and history of splenectomy with portal-azygous disconnection during the treatment of portal hypertension. According to the Child-Pugh classification, these cases were graded as A, B, and C. And according to the ranges of the normal reference values of the data, they were categorized into two groups including a normal group and an abnormal group.The data mainly comes from FMMU and Xi'an jiaotong university from the year of 2002 to 2012.

Eligibility criteria: Inclusion Criteria:

* after surgery

Exclusion Criteria:

* without surgery

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Chen yong
state: Shaanxi
Study officials:
affiliation: Xia jielai
name: Chen yong, professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT00563355: A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients
Official title: A Prospective Randomised Controlled Trial to Study the Effects of Recombinant Human Erythropoietin on the Progression of Atherosclerosis, Cardiovascular Function, Nutrition and Residual Renal Function in Pre-dialysis Chronic Renal Failure Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Disease
Kidney Diseases
Cardiovascular Diseases
Keywords: chronic kidney disease
cardiovascular disease
Lead sponsor: Hospital Authority, Hong Kong
Sponsor class: OTHER_GOV
Collaborators: name: The Hong Kong Society of Nephrology
First posted: 2007-11-26
Enrollment: 66
Sex: ALL
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary aim of the study is to evaluate the effects of correction of anemia using erythropoietin on the progression of atherosclerosis and cardiac muscle thickening in patients with chronic kidney disease


Eligibility criteria: Inclusion Criteria:

* Patients with chronic renal failure with serum creatinine between 150umol/L and 800umol/L and at the same time Hb
* Patients with regression line of 1/serum creatinine versus time showing that they may not require dialysis within the coming 12 months
* Patients below the age of 75

Exclusion Criteria:

* Patients with valvular heart disease/congenital heart disease
* Patients with ischemic heart disease/history of myocardial infarction/coronary artery bypass surgery
* Patients with history of heart failure
* Patients with regression line of 1/serum creatinine versus time showing that the estimated date of end stage renal disease is within 12 months
* Patients with thalassemic trait or haemoglobinopathies
* Patients with underlying haematological malignancies
* Patients with active bleeding
* Patients with uncorrected iron or other vitamins deficiencies
* Patients with poor general condition

Primary outcomes:
measure: endothelial function and atherosclerosis
timeFrame: 6 month, 1 year
measure: cardiac hypertrophy and cardiac function
timeFrame: 6 month, 1 year
Secondary outcomes:
measure: nutrition status
timeFrame: 6 month, 1 year
measure: residual renal function
timeFrame: 6 month, 1 year
measure: quality of life
timeFrame: 6 month, 1 year
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Prince of Wales Hospital
Study officials:
affiliation: Department of Medicine & Therapeutics/Nephrology, Prince of Wales Hospital/ The Chinese University of Hong Kong
name: Angela YM Wang, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05095155: Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh Nationality
Official title: Preventive and Personalized Medicine (2021-2023)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: B Cell Leukemia
Lymphoma
Keywords: SNP
Lead sponsor: Asfendiyarov Kazakh National Medical University
Sponsor class: OTHER
First posted: 2021-10-27
Enrollment: 400
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children of the Kazakh population

Brief summary: To search for a genetic marker of B-cell leukemias and lymphomas in children of Kazakh nationality, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with B-cell leukemias and lymphomas in children of Kazakh nationality and normal control will be performed.


Eligibility criteria: Inclusion Criteria:

* ethnicity - Kazakhs in at least three generations
* active disease or a history of B-line ALL or B-NHL, established on the basis of morphological, cytochemical, immunophenotypic or immunohistochemical research methods with confirmation of the fact of the disease in medical documentation
* Signed voluntary informed consent of the legal representative to participate in the project

Exclusion Criteria:

* Children suffering from other types of malignant neoplasms
* Children with B-linear leukemia and lymphomas with concomitant specified genetic and chromosomal diseases
* Children of non-Kazakh nationality
* Absence of signed informed consent or informed refusal of the legal representative to participate in the study before starting therapy

Primary outcomes:
measure: Associated with B-cell lymphoma and B-cell acute lymphoblastic leukemia
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Almaty
country: Kazakhstan
facility: Scientific Center of Pediatrics and Pediatric Surgery
Study officials:
affiliation: JSC "Scientific Center of Pediatrics and Pediatric Surgery"
name: Riza Boranbayeva, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02973555: Platelet-Rich Protein and the Endometrium
Official title: Can Platelet-rich Plasma (PRP) Promote Endometrial Growth and Improve Pregnancy Outcome of Patients With Thin Endometrium Undergoing Assisted Reproductive Technology (ART) Treatments?
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Infertility
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2016-11-25
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 54
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Platelet-rich plasma (PRP) may promote the endometrial growth and improve pregnancy outcome of patients with thin endometrium undergoing ART treatments.


Eligibility criteria: Inclusion Criteria:

* Women undergoing a frozen thawed embryo transfer cycle with poor endometrial response to estrogen (\< 7 mm) after at least two standard preparation protocols, of which one was canceled due to thin endometrium

Exclusion Criteria:

* none

Primary outcomes:
measure: endometrial thickness >7mm
timeFrame: 1 month
Secondary outcomes:
measure: Positive serum pregnancy test
timeFrame: 14 days post embryo transfer
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
affiliation: Hadassah Medical Organization
name: Ronit Kochman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06323655: Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects
Official title: A Randomized, Double-blind, Double-dummy, Placebo-controlled, Three-way Crossover Study in Healthy Subjects to Evaluate the Next-day Residual Effects of 20 mg Tasimelteon
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Vanda Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2024-03-21
Enrollment: 48
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of this study is to investigate next-day residual effects of tasimelteon compared with placebo and active control in healthy subjects.


Eligibility criteria: Inclusion Criteria:

* Ability to provide written consent;
* Healthy subjects with no medical, psychiatric, or current sleep disorders;
* Men and women ages 21 - 55, inclusive;
* Possession of a valid driver's license ≥ 3 years with reported annual mileage ≥ 3,000 km.

Exclusion Criteria:

* Pregnancy or recent pregnancy;
* Subjects who are unable to read or speak English or French.

Primary outcomes:
measure: Next-day effects on simulated driving performance as measured by changes in Standard Deviation of Lateral Position (SDLP)
timeFrame: Day 1 of Treatment Period 1, Treatment Period 2, and Treatment Period 3 (each Period is 1 day, separated by washout)
Secondary outcomes:
Other outcomes:
Locations:
city: Laval
country: Canada
facility: Vanda Investigational Site
state: Quebec
Study officials:
References:
Clinical trial NCT06844955: Smart Diabetic Foot Care Application
Official title: Impact of Using a Smart Diabetic Foot Care Application on Patients' Knowledge and Self-management
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Diabetic Foot
Lead sponsor: National Taipei University of Nursing and Health Sciences
Sponsor class: OTHER
First posted: 2025-02-25
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Collect diabetes cases from a Christian hospital in the northeast that agrees to join this program

Brief summary: This study developed an app for the guidance of home-based diabetic foot care to explore its impact on patients' foot assessment awareness and self-care behavior after using this app. The study also assessed the app's effectiveness in cultivating behavioral habits that are effective in managing diabetes.

Detailed description: Diabetes is a common chronic metabolic disease worldwide. Approximately 50% to 60% of ulcers caused by diabetes become infected, and moderate to severe infections can lead to lower limb amputation. Among amputees, the five-year mortality rate exceeds 70%.Smart devices (mobile phones, computers, etc.) are indispensable necessities to modern lives. Downloadable mobile health applications (mHealth Apps) on smartphones are widely used in medical care . The use of these apps on smartphones has created a new field in the health industry known as mobile health

Eligibility criteria: Inclusion Criteria:

1. Clinical diagnosis of type 2 diabetes .
2. Aged between 20 and 80 years.
3. Able to use mobile apps or tablets for health management .

Exclusion Criteria:

1. Patients who were unconscious, had delirium, were bedridden, had cognitive impairment, or were unable to perform daily self-care.
2. Patients who refused to participate.

Primary outcomes:
measure: Foot ulcers
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taipei university of nursing and health science
Study officials:
References:
Clinical trial NCT00120055: Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Myopathy
Lead sponsor: University of Oslo School of Pharmacy
Sponsor class: OTHER
First posted: 2005-07-14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study is to investigate whether the pharmacokinetics of atorvastatin and/or its metabolites is altered in patients with confirmed atorvastatin-induced myopathy compared to healthy controls.

Detailed description: A 24 hour pharmacokinetic investigation of atorvastatin and metabolites will be performed in 15 patients with a history of atorvastatin -induced myotoxicity. The possible link to relevant mutations in SLCO1B1, CYP3A5 and MDR1 will be also be investigated

Eligibility criteria: Inclusion Criteria:

* above 18 years
* previous history of atorvastatin-associated myotoxicity

Exclusion Criteria:

* current treatment with drugs or herbal remedies with known pharmacokinetic interaction potential with atorvastatin
* previous CK levels above ten times the upper limit of normal range
* pregnancy and persistent muscular complaints after a four week wash-out period of statin treatment

Primary outcomes:
measure: Statin toxicity
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Oslo School of Pharmacy
name: Anders Åsberg, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT05401955: Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD)
Official title: Effects of a Physical Therapy and Therapeutic Exercise Program in Graft-versus-host Disease (GVHD)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: GVHD,Acute
GVHD, Chronic
Lead sponsor: University of Salamanca
Sponsor class: OTHER
First posted: 2022-06-02
Enrollment: 12
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Range of motion, antropometric measurements, quality of life questionnaire and 2 minutes walk test will be implemented as an initial assessment.

Physical exercise program will take 2 sessions a week for six months, and several follow-ups: before, during and after treatment.


Eligibility criteria: Inclusion Criteria:

* Allogenic Transplantation patients with Graft versus host disease

Exclusion Criteria:

* Cognitive impairment
* Physical limitation from other pathologies

Primary outcomes:
measure: SF36 Questionnaire
timeFrame: baseline and post-intervention (24 weeks)
measure: 2 minutes walk test
timeFrame: baseline and post-intervention (24 weeks)
measure: Hands strength
timeFrame: baseline and post-intervention (24 weeks)
measure: Active range of motion
timeFrame: baseline and post-intervention (24 weeks)
Secondary outcomes:
Other outcomes:
Locations:
city: Salamanca
country: Spain
facility: University of Salamanca
Study officials:
References:
Clinical trial NCT06380855: Flexible Colonoscope Assisted Hybrid Transanal Total Mesorectal Resection (taTME)
Official title: Flexible Colonoscope Assisted Hybrid Transanal Total Mesorectal Resection (taTME)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Rectal Cancer
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2024-04-24
Enrollment: 5
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients suitable for transanal endoscopic surgery

Brief summary: The investigators propose to use flexible endoscopy combined with transanal total mesorectal resection to further reduce anal injury.

Detailed description: Endoscopic technique has become an indispensable part of Natural orifice transluminal endoscopic surgery (NOTES). However, the upper gastrointestinal tract is easy to cause severe leakage complications, which mainly limits the application of endoscopy in rectum. Herein, investigators propose purse suture closing distal rectum and full-layer incision of the rectal wall using flexible endoscopic from anal to assist in hybrid transanal total mesorectal resection (taTME).Further reduce the damage of anus caused by taTME.

Eligibility criteria: Inclusion Criteria:

1. Age between 18 and 80 years old
2. Confirmed rectal adenocarcinoma cancer pathologically
3. tumor location ≦ 12 cm from the anal margin
4. Willing and able to provide written informed consent for participation in this study

Exclusion Criteria:

1. distant metastasis before surgery
2. more than one colorectal tumor at diagnosis
3. familial adenomatous polyposis
4. recurrent rectal cancer
5. undergo transanal minimally invasive surgery
6. undergo palliative treatment
7. undergo emergency surgery

Primary outcomes:
measure: Success rate of operation
timeFrame: 1 years after the surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Department of colorectal surgery, the Sixth Affiliated Hospital, Sun Yat-Sen University
state: Guangdong
Study officials:
References:
Clinical trial NCT04478955: Effect of Eye Make up on Ocular Surface
Official title: Effect of Pencil Eyeliners and Waterproof Mascara on Tear Stability Tests and Meibomography
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Meibomian Gland Dysfunction
Keywords: meibomian, eyeliner
Lead sponsor: Erol Olcok Corum Training and Research Hospital
Sponsor class: OTHER
First posted: 2020-07-21
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 18 to 35 year old females with eyeliner, mascara or combined use for study groups 18 to 35 year old females with no make up use for control group

Brief summary: The aim of this study is to compare the degree of tear film instability and severity of meibomian gland loss between subjects who use eyeliner, mascara, a combination of both and those who do not use eyeliner.


Eligibility criteria: Inclusion Criteria:

To use eyeliner/mascara or combined for at least 3 days for 6 months for study groups No routine eye make up use for the cıontrol group

-

Exclusion Criteria:

* any systemic or ocular disease taht can affect ocular surface

Primary outcomes:
measure: Schirmer test
timeFrame: 5 minutes
Secondary outcomes:
measure: Non contact tear break up test
timeFrame: 17 seconds
measure: Meibomography
timeFrame: 2 minutes
Other outcomes:
Locations:
city: Corum
country: Turkey
facility: ErolOlcok Corum WEducatin and Research Hospital
Study officials:
References: